This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Levetiracetam
FDA-approved antiepileptic drug, not a nootropic.
Aliases (9)
Overview
What is Levetiracetam?
Levetiracetam (Keppra) is a pyrrolidone-derivative antiepileptic drug. It is FDA-approved for partial-onset, myoclonic, and tonic-clonic seizures and used off-label for anxiety and certain neurodegenerative conditions.
Key Benefits
Effective broad-spectrum seizure control with a clean PK profile, no significant CYP interactions, and possible cognitive benefit at low doses in early AD or hippocampal hyperexcitability.
Mechanism of Action
Binds the synaptic vesicle protein SV2A, modulating neurotransmitter release in hyperactive neurons. Also reduces high-voltage-activated calcium currents and AMPA-mediated excitatory transmission.
Pharmacokinetics
▸Brand options6 known
Status"**US: Rx only (Schedule: not controlled).** FDA-approved 1999 (UCB Pharma) for adjunctive partial-onset seizures in adults; 2006 monotherapy partial-onset; 2007 myoclonic seizures in juvenile myoclonic epilepsy; 2008 primary generalized tonic-clonic seizures. Generic since 2008. **EU/UK Rx (Keppra, UCB Pharma + many generics).** **India Rx but de facto OTC** at most pharmacies. Not WADA-prohibited. **Boxed/black-box-adjacent FDA warnings:** suicidal ideation/behavior risk class warning shared with all AEDs; psychiatric AEs prominent on label."
Peptide Interactions
(clinically — for refractory epilepsy). Not relevant for nootropic context.
(if ever used) — reported to reduce Keppra-rage incidence in pediatric literature; mechanism unclear. Worth mentioning for completeness.
not because of pharmacological interaction (the mechanisms don't conflict), but because stacking an anticonvulsant with cognitive enhancers makes no sense: t…
mechanistically similar (~15-30× higher SV2A affinity); same concerns at higher potency. No reason to stack two SV2A ligands.
(alcohol, benzodiazepines, opioids, sedating antihistamines) — additive somnolence / sedation. the user: zero alcohol baseline, so this is a non-issue, but w…
polypharmacy AED exposure increases AE risk without benefit outside epilepsy management.
(DHA, Mg threonate, citicoline, NAC, PS, curcumin, rhodiola, theanine, glycine, D3+K2, beta-alanine, vitamin C) — no known interactions. Levetiracetam's clea…
no PK interaction; opposing effects (modafinil pro-cognitive, levetiracetam neutral-to-blunting); no reason to combine.
no interaction.
no interaction.
Quality Indicators
Pharmacy-dispensed, intact packaging
Prescription tablets in original sealed packaging from a licensed pharmacy.
Generic vs branded
Generics are usually fine but bioavailability can vary slightly; track if you switch.
Unbranded blister or counterfeit risk
Counterfeit pharmaceuticals are a known issue; verify pharmacy and lot if buying internationally.
What to Expect
- Day 1PK-driven acute peak per administration. Verify dose tolerated.
- Week 1Steady-state reached for most daily-dosed pharma.
- Week 2-4Therapeutic effect established; titration window if needed.
- Long-termPeriodic monitoring per drug class (labs, BP, ECG as applicable).
Side Effects & Safety
Common (>10% users at clinical doses):
- Somnolence (15-25%)
- Asthenia / fatigue (10-15%)
- Headache
- Infection (mild URI / nasopharyngitis — class effect for AEDs)
- Irritability / "Keppra rage" subset (10-20% — see below)
- Dizziness
Less common (1-10%):
- Depression, anxiety, mood lability
- Nervousness, agitation
- Psychotic symptoms (rare but documented — hallucinations, paranoia)
- Anorexia, nausea
- Vertigo, ataxia
- Weight changes
- Skin rash (mild — not the high-risk SJS/TEN signal seen with carbamazepine, lamotrigine)
Rare-serious (<1% but worth knowing):
- Suicidal ideation / behavior — class warning across all AEDs (FDA 2008 class label change). Levetiracetam carries the warning.
- Psychotic episodes — rare, mostly in patients with prior psychiatric history.
- Stevens-Johnson Syndrome / TEN — extremely rare with levetiracetam (much lower than carbamazepine, lamotrigine, phenytoin), but case reports exist.
- Pancytopenia / leukopenia / thrombocytopenia — rare hematologic AEs (UCB postmarketing signal).
- Hyponatremia — rare case reports.
- Acute kidney injury / interstitial nephritis — very rare.
- Pancreatitis — very rare.
Specific watch period — "Keppra rage" (the dominant practical concern):
- Onset typically within first 4-8 weeks of starting or up-titrating.
- Manifests as: irritability, anger outbursts, frustration intolerance, anxiety, depression, suicidality.
- Approximately 10-20% of users develop clinically meaningful psychiatric AEs, with 5-10% discontinuing for behavioral reasons (varies by study and population — pediatric and prior-psychiatric-history patients are higher-risk).
- Vitamin B6 (pyridoxine) supplementation is reported to reduce Keppra-rage symptoms in some pediatric epilepsy literature (e.g., Major et al.), and is sometimes used clinically as an AE-mitigation strategy. Mechanism unclear (possibly GABA-precursor enhancement).
- Dose-dependent: AE frequency rises with dose, but psychiatric AEs are reported even at low doses, including at 125 mg BID.
- For this-archetype (20yo, no psychiatric history, combat athlete with affect-modulation needs): this AE profile is disqualifying for daily nootropic use, full stop.
MMA-specific consideration: Levetiracetam is not WADA-prohibited, but the somnolence + processing-speed slowing + emotional blunting at clinical doses would meaningfully impair training performance and reaction time. At 125 mg BID, these effects are mild but still net-negative for a combat-sport context.
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.